Antihypertensive drugs

被引:212
作者
Laurent, Stephane [1 ,2 ]
机构
[1] Paris Descartes Univ, Hop Europeen Georges Pompidou, AP HP, Dept Pharmacol, 56 Rue Leblanc, F-75015 Paris, France
[2] Paris Descartes Univ, Hop Europeen Georges Pompidou, AP HP, INSERM,U970, 56 Rue Leblanc, F-75015 Paris, France
关键词
Diuretic; Betablocker; Angiotensin-converting enzyme inhibitor; Angiotensin II receptor antagonist; Calcium channel blocker; CONVERTING-ENZYME-INHIBITION; HIGH BLOOD-PRESSURE; PHARMACOLOGICAL-PROPERTIES; ESSENTIAL-HYPERTENSION; CARDIOVASCULAR EVENTS; RESISTANCE ARTERIES; CHANNEL OPENERS; THERAPEUTIC-USE; END-POINTS; ANGIOTENSIN;
D O I
10.1016/j.phrs.2017.07.026
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Successful treatment of hypertension is possible with limited side effects given the availability of multiple antihypertensive drug classes. This review describes the various pharmacological classes of antihypertensive drugs, under two major aspects: their mechanisms of action and side effects. The mechanism of action is analysed through a pharmacological approach, i.e. the molecular receptor targets, the various sites along the arterial system, and the extra-arterial sites of action, in order to better understand in which type of hypertension a given pharmacological class of antihypertensive drug is most indicated. In addition, side effects are described and explained through their pharmacological mechanisms, in order to better understand their mechanism of occurrence and in which patients drugs are contra-indicated. This review does not address the effectiveness of monotherapies in large randomized clinical trials and combination therapies, since these are the matters of other articles of the present issue. Five major pharmacological classes of antihypertensive drugs are detailed here: beta-blockers, diuretics, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium channel blockers. Four additional pharmacological classes are described in a shorter manner: renin inhibitors, alpha-adrenergic receptor blockers, centrally acting agents, and direct acting vasodilators. (C) 2017 Published by Elsevier Ltd.
引用
收藏
页码:116 / 125
页数:10
相关论文
共 72 条
[1]   Effects of antihypertensive treatment on small artery remodelling [J].
Agabiti-Rosei, Enrico ;
Heagerty, Anthony M. ;
Rizzoni, Damiano .
JOURNAL OF HYPERTENSION, 2009, 27 (06) :1107-1114
[2]  
[Anonymous], HYPERTENSION WB
[3]   TREATMENT OF DRUG-RESISTANT HYPERTENSION WITH MINOXIDIL OR ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR - BLOOD-PRESSURE, RENIN, ALDOSTERONE, AND ELECTROLYTE RESPONSES [J].
BAER, L ;
RADICHEVICH, I ;
WILLIAMS, GS .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1980, 2 :S206-S216
[4]   Meta-analysis of 94,492 patients with hypertension treated with beta Blockers to determine the risk of new-onset diabetes Mellitus [J].
Bangalore, Sripal ;
Parkar, Sanobar ;
Grossman, Ehud ;
Messerli, Franz H. .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (08) :1254-1262
[5]   Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy [J].
Barnett, AH ;
Bain, SC ;
Bouter, P ;
Karlberg, B ;
Madsbad, S ;
Jervell, J ;
Mustonen, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (19) :1952-1961
[6]   IMIDAZOLINE RECEPTORS - A NEW CONCEPT IN CENTRAL REGULATION OF THE ARTERIAL BLOOD-PRESSURE [J].
BOUSQUET, P ;
FELDMAN, J ;
TIBIRICA, E ;
BRICCA, G ;
GRENEY, H ;
DONTENWILL, M ;
STUTZMANN, J ;
BELCOURT, A .
AMERICAN JOURNAL OF HYPERTENSION, 1992, 5 (04) :S47-S50
[7]   Pharmacological Modulation of Arterial Stiffness [J].
Boutouyrie, Pierre ;
Lacolley, Patrick ;
Briet, Marie ;
Regnault, Veronique ;
Stanton, Alice ;
Laurent, Stephane ;
Mahmud, Azra .
DRUGS, 2011, 71 (13) :1689-1701
[8]   Amlodipine-Valsartan Combination Decreases Central Systolic Blood Pressure More Effectively Than the Amlodipine-Atenolol Combination The EXPLOR Study [J].
Boutouyrie, Pierre ;
Achouba, Assya ;
Trunet, Patrick ;
Laurent, Stephane .
HYPERTENSION, 2010, 55 (06) :1314-U54
[9]   Verapamil - A review of its pharmacological properties and therapeutic use in coronary artery disease [J].
Brogden, RN ;
Benfield, P .
DRUGS, 1996, 51 (05) :792-819
[10]   DILTIAZEM - A REAPPRAISAL OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE [J].
BUCKLEY, MMT ;
GRANT, SM ;
GOA, KL ;
MCTAVISH, D ;
SORKIN, EM .
DRUGS, 1990, 39 (05) :757-806